Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Walter Lin

Plastic Surgery San Francisco, CA Medical Doctor

NPI 1679862635 CMS profile 1208048

Ucsf Department Of Surgery, 513 Parnassus Avenue, S-321, San Francisco, CA 94143

Open in the dashboard

General payments

$68,423

188 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Walter Lin of San Francisco, CA is reported in the CMS Open Payments database as having received $68,423 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47,331 68
2024 General $9,555 40
2023 General $1,296 10
2022 General $1,336 10
2021 General $279 12
2020 General $4,288 16
2019 General $4,339 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Walter Lin
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Walter Lin were reported at $47,331. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Walter Lin Plastic Surgery median Middle half National median
2019 $4,339 $371 $122–$1,483 $163
2020 $4,288 $158 $52–$438 $114
2021 $279 $249 $87–$752 $132
2022 $1,336 $274 $102–$793 $149
2023 $1,296 $299 $113–$891 $160
2024 $9,555 $361 $124–$1,062 $164
2025 $47,331 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alafair Biosciences,Inc. $52,452 63 payments
  2. AxoGen $9,399 34 payments
  3. Tactile Systems Technology Inc $2,599 11 payments
  4. Baxter Healthcare $667 5 payments
  5. PolyNovo North America LLC $417 5 payments
  6. Stryker Corporation $373 3 payments
  7. Avita Medical Americas, LLC $366 5 payments
  8. Biocircuit Technologies Inc $197 1 payment
  9. Tulavi Therapeutics, Inc. $196 1 payment
  10. Integra LifeSciences Corporation $186 5 payments
  11. Other $1,570 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41,525 14 payments
  2. Travel and Lodging $12,754 29 payments
  3. Food and Beverage $9,085 140 payments
  4. Consulting Fee $4,969 4 payments
  5. Education $90 1 payment
Products named General payments · program years 2019–2025
  1. VersaWrap $52,452 63 payments
  2. AXOGUARD NERVE PROTECTOR $8,090 29 payments
  3. AxoGuard Nerve Connector $8,090 29 payments
  4. Avance Nerve Graft $5,439 14 payments
  5. Flexitouch Plus $2,514 8 payments
  6. Entre Plus $2,346 6 payments
  7. AXOGUARD NERVE CAP $659 7 payments
  8. Axoguard HA+ Nerve Protector $659 7 payments
  9. No Related Product $581 3 payments
  10. NOVOSORB BTM $373 3 payments
  11. Other $4,454 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$35,008

Medicare's payments for the services billed

Medicare patients

72

Average age 73

Services billed

220

50 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 64%
High blood pressure 54%
Cancer 29%
Depression 28%
Osteoporosis 25%
Ischemic heart disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record